Form 8-K - Current report:
SEC Accession No. 0001213900-23-090252
Filing Date
2023-11-27
Accepted
2023-11-27 16:55:37
Documents
12
Period of Report
2023-11-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea189022-8k_nektarther.htm   iXBRL 8-K 26579
  Complete submission text file 0001213900-23-090252.txt   198186

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nktr-20231124.xsd EX-101.SCH 3009
3 XBRL LABEL FILE nktr-20231124_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE nktr-20231124_pre.xml EX-101.PRE 22355
6 EXTRACTED XBRL INSTANCE DOCUMENT ea189022-8k_nektarther_htm.xml XML 3213
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 231440858
SIC: 2834 Pharmaceutical Preparations